Mezzion Pharma
140410.KQ
100.61 USD
-3.07
-2.96%
m
Overview
Last close
100.61 usd
Market cap
859.83M usd
52 week high
120.68 usd
52 week low
17.68 usd
Target price
270.41 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
563.6071
Price/Book Value
117.5859
Enterprise Value
3.03B usd
EV/Revenue
564.3838
EV/EBITDA
-15.9681
Key financials
Revenue TTM
20.95M usd
Gross Profit TTM
2.56M usd
EBITDA TTM
-13.40M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
62.74M usd
Net debt
N/A usd
About
Mezzion Pharma Co.,Ltd. engages in the development, licensing, and commercialization of drugs for the treatment of vascular diseases. It is developing Udenafil, a PDE5 inhibitor to treat erectile dysfunction, benign prostatic hyperplasia, pulmonary arterial hypertension, overactive bladder, hepatic portal hypertension, and chronic obstructive pulmonary diseases. The company was formerly known as Dong-A Pharmtech Co., Ltd. and changed its name to Mezzion Pharma Co.,Ltd. in April 2013. Mezzion Pharma Co.,Ltd. was founded in 2002 and is based in Seoul, South Korea.
- Symbol140410.KQ
- ExchangeKQ
- IsinKR7140410002
- CountrySouth Korea
- SectorHealthcare
- IndustryPharmaceuticals
- CEOMr. Dong-Hyun Park
- HeadquarterSeoul
- Web sitehttps://www.mezzion.co.kr
